Andrew Guggenhime serves as the President and Chief Financial Officer at VAXCYTE INC, a biotechnology company focused on developing novel vaccines to prevent or treat bacterial infectious diseases. With a robust background in finance and strategic operations, Guggenhime has been instrumental in guiding VAXCYTE through its growth phases and toward achieving its mission of delivering transformative vaccines. Prior to joining VAXCYTE, Guggenhime held several high-profile positions in the biotechnology and pharmaceutical sectors. He was the Executive Vice President and Chief Financial Officer at Global Blood Therapeutics, where he played a pivotal role in the company's successful IPO and subsequent growth. Before that, he spent over a decade at Jazz Pharmaceuticals, eventually rising to the position of Executive Vice President and Chief Financial Officer. His tenure at Jazz Pharmaceuticals was marked by significant financial achievements, including leading the company through multiple acquisitions and financings that bolstered its market position. Guggenhime's extensive experience in financial strategy and operations has been a key asset to VAXCYTE as it navigates the complex landscape of vaccine development and commercialization. As President and CFO at VAXCYTE, Guggenhime is responsible for overseeing the company's financial strategy, which includes managing capital raising efforts, financial planning, and investor relations. His leadership has been crucial in securing the funding necessary to advance VAXCYTE's clinical programs and expand its research capabilities. Under his guidance, VAXCYTE has made significant strides in developing its lead vaccine candidate, aimed at preventing pneumococcal disease, demonstrating his ability to translate financial acumen into tangible progress in the biotech arena. Guggenhime's strategic vision and operational expertise continue to drive VAXCYTE toward its goal of becoming a leader in the global vaccine market.